This week in Drug Discovery (8 – 12 December)
News round-up for 8 – 12 December by Bruno Quinney, Content Team at DDW.
This week in DDW, innovative treatments have been developed for neurodegenerative diseases, allergies and arthritis. Elsewhere, China is becoming the dominant force in the biotech sector.
The top stories:
Once-a-day pill could reverse cognitive decline, trial shows
Tazbentetol demonstrated rapid, sustained cognitive improvement in a Phase IIa trial. The randomised, double-blind, placebo-controlled trial enrolled 24 patients in Australia, with Tazbentetol proving to be a safe and effective drug with cognitive improvement increasing over time.
Read more…
Immunotherapy could treat nut allergies, results show
VLP Peanut reached its primary endpoint in the Phase I/IIa PROTECT trial, with results showing the immunotherapy was safe and well-tolerated.
Gum cells show potential as cure for knee arthritis
The world’s first patient has been treated for knee osteoarthritis (OA) using gum cells from a human donor.
Lilly begins obesity trial in the UK
The first patient visit for Lilly’s five-year clinical trial assessing the company’s type-2 diabetes and weight-loss drug tirzepatide has taken place.
China becoming dominant force in biotech sector, survey says
ICON’s global biotech sector survey, capturing insights from more than 260 biotech professionals and venture capital executives, found that China is cementing its dominance in the sector and Western biotechs must adapt to maintain competitiveness.